Affymetrix may not technically be a "new company," as one analyst recently called it, but its fourth quarter results revealed a firm with revenue growth driven by success in markets different from the ones it targeted just a few years ago.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.
Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.
Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.
A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.